Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 7 of 696 for:    sickle cell disease

Hydroxyurea in the Treatment of Sickle Cell Disease

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02709681
Recruitment Status : Completed
First Posted : March 16, 2016
Last Update Posted : October 6, 2017
Sponsor:
Information provided by (Responsible Party):
Società Italiana Talassemie ed Emoglobinopatie

Brief Summary:
This is a retrospective cohort study of Sickle Cell Disease (SCD) patients attending 32 treatment centers across Italy. The aim of this study will be to report the Italian experience with the use of hydroxyurea in a large cohort of SCD patients and to evaluate the benefits and safety of this intervention for the prevention and management of a wide range of clinical morbidities

Condition or disease Intervention/treatment
Sickle Cell Disease Other: Physician standard-of-care in SCD patients

Detailed Description:

The indication for hydroxyurea initiation was 2-3 vaso-occlusive crisis and/or hospitalizations in the last year.

The study will analyze demographics (age and gender), origin, genotype, clinical phenotype (vaso-occlusive or hemolytic), transfusion history (including exchange), and folic acid use, average laboratory values up to three years pre-hydroxyurea and for the period post-hydroxyurea therapy including total hemoglobin level, fetal hemoglobin level, hemoglobin S level, white blood count, platelet count, lactate dehydrogenase level, total and direct bilirubin levels, aspartate and alanine aminotransferase levels, and serum creatinine level.

The incidence of complications pre- and post-hydroxyurea therapy will be also analyzed including: stroke, silent cerebral infraction, acute chest syndrome, vaso-occlusive crisis, hospitalization, pulmonary hypertension, leg ulcers, bone necrosis, and kidney injury. Safety data included adverse events as reported by the treating physician and the incidence of malignancy or death as well as pregnancy incidents and their outcomes will be also pointed out.


Layout table for study information
Study Type : Observational
Actual Enrollment : 628 participants
Observational Model: Cohort
Time Perspective: Retrospective
Official Title: Hydroxyurea in Sickle Cell Disease: a Large Nation-wide Cohort Study From Italy
Study Start Date : November 2015
Actual Primary Completion Date : November 2016
Actual Study Completion Date : July 2017

Resource links provided by the National Library of Medicine

Drug Information available for: Hydroxyurea

Group/Cohort Intervention/treatment
SCD patients
Patients followed in 32 Italian Centers.
Other: Physician standard-of-care in SCD patients



Primary Outcome Measures :
  1. Changes in laboratory parameters is being assessed [ Time Frame: An average of 3 years before and an average of 3 years after initiation of hydroxyurea therapy ]
    Increases or decreases in percentage of total hemoglobin, fetal hemoglobin and hemoglobin S level will be assessed. Changing of white blood cells and platelets counts, lactate dehydrogenase, bilirubin, aspartate aminotransferase and serum creatinine level will be also evaluated.

  2. Changes in complication rates is being assessed [ Time Frame: An average of 3 years before and an average of 3 years after initiation of hydroxyurea therapy ]
    Changing in the incidence of stroke, silent cerebral infraction, acute chest syndrome, vaso-occlusive crisis, pulmonary hypertension, leg ulcers, bone necrosis and kidney injury will be evaluated.

  3. Rate of hospitalizations [ Time Frame: An average of 3 years before and an average of 3 years after initiation of hydroxyurea therapy ]
    Changing in rate of hospitalizations before and after start hydroxyurea therapy


Secondary Outcome Measures :
  1. Changing in the incidence of complications according to specific subgroups [ Time Frame: An average of 3 years before and an average of 3 years after initiation of hydroxyurea therapy ]
    We also stratified the analysis according to age (≥18 years), origin (Italian and African), genotype (βS/β0, βS/β+ and βS/βS) duration of hydroxyurea treatment (≥10 years) and hydroxyurea dose(≥15 mg/kg/day).



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   1 Year and older   (Child, Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
A population of SCD (Homozigous HbS and Beta Thal /HbS) patients followed in 32 Italian Centers was included in this analysis.
Criteria

Inclusion Criteria:

  • Sickle Cell Disease affected patients
  • 2-3 vaso-occlusive crisis and/or hospitalizations in the last year

Exclusion Criteria

  • none

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02709681


Locations
Layout table for location information
Italy
Ospedali Civili Riuniti di Sciacca
Sciacca, Agrigento, Italy, 92019
Ospedale Vittorio Emanuele III
Gela, Caltanisetta, Italy, 93012
Azienda Ospedaliero-Universitaria
Bari, Italy
U.O. Oncoematologia Pediatrica Ospedali Civili
Brescia, Italy, 25100
Ospedale "A. Perrino"
Brindisi, Italy, 72100
Azienda Ospedaliera Universitaria Di Cagliari
Cagliari, Italy, 09121
Ospedale Vittorio Emanuele
Catania, Italy, 95123
ARNAS "Garibaldi"
Catania, Italy, 95124
University of Catania
Catania, Italy, 95124
A.O. "Pugliese-Ciaccio"
Catanzaro, Italy, 88100
Osp.San Giovanni Di Dio
Crotone, Italy
Azienda Ospedaliero Universitaria Meyer
Firenze, Italy, 50139
E.O. Ospedali Galliera
Genova, Italy, 16128
Università degli Studi di Milano
Milano, Italy, 20122
Azienda Ospedaliero-Universitaria di Modena - Policlinico
Modena, Italy, 41124
Clinica pediatrica Monza S. Gerardo
Monza, Italy, 20052
Azienda Ospedaliera San Gerardo di Monza
Monza, Italy, 20900
Aorn A. Cardarelli
Napoli, Italy
Clinica di Onco-Ematologia Pediatrica, Università di Padova
Padova, Italy, 35128
A.R.N.A.S. "Civico"
Palermo, Italy, 90100
Azienda Ospedaliera Ospedali Riuniti Villa Sofia Cervello
Palermo, Italy, 90146
Azienda Ospedaliero-Universitaria di Parma
Parma, Italy, 43126
Policlinico San Matteo
Pavia, Italy, 27100
Centro Emofilia e Medicina Trasfusionale - Pres. Ospedaliero
Ravenna, Italy, 48121
A. O. Bianchi Melacrino Morelli
Reggio Calabria, Italy, 89100
Ospedale S. Eugenio - FF UOSD DH Talassemici
Roma, Italy, 00144
Università Cattolica del Sacro Cuore - Policlinico A.Gemelli
Roma, Italy, 00168
U.O.S. Talassemia P.O. Umberto I°
Siracusa, Italy, 96100
Università degli Suidi di Torino
Torino, Italy, 90146
Policlinico G.B. Rossi
Verona, Italy, 37122
Sponsors and Collaborators
Società Italiana Talassemie ed Emoglobinopatie
Investigators
Layout table for investigator information
Principal Investigator: Paolo Rigano, MD Servico Integrado de Tecnicas Endovasculares

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Layout table for additonal information
Responsible Party: Società Italiana Talassemie ed Emoglobinopatie
ClinicalTrials.gov Identifier: NCT02709681     History of Changes
Other Study ID Numbers: SocietaITE
First Posted: March 16, 2016    Key Record Dates
Last Update Posted: October 6, 2017
Last Verified: March 2016
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No
Keywords provided by Società Italiana Talassemie ed Emoglobinopatie:
Sickle Cell Disease
Hydroxyurea
Additional relevant MeSH terms:
Layout table for MeSH terms
Anemia, Sickle Cell
Hematologic Diseases
Genetic Diseases, Inborn
Anemia, Hemolytic, Congenital
Anemia, Hemolytic
Anemia
Hemoglobinopathies
Hydroxyurea
Antineoplastic Agents
Antisickling Agents
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Nucleic Acid Synthesis Inhibitors